Advertisement

Topics

US regulatory submission for mepolizumab as EGPA treatment

08:27 EDT 29 Jun 2017 | thePharmaLetter

UK pharma major GlaxoSmithKline has filed for US approval for an expanded indication of its an interleukin-5…

Original Article: US regulatory submission for mepolizumab as EGPA treatment

NEXT ARTICLE

More From BioPortfolio on "US regulatory submission for mepolizumab as EGPA treatment"

Quick Search
Advertisement
 

Relevant Topic

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...